JEOL Ltd
TSE:6951
Net Margin
JEOL Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
JEOL Ltd
TSE:6951
|
227.1B JPY |
15%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
215.6B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.4B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
136.5B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
132.9B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.9B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.7B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.6B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
40.2B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
259.5B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
31.2B USD |
23%
|
JEOL Ltd
Glance View
In the bustling world of advanced scientific instrumentation, JEOL Ltd. has carved a distinguished niche for itself as a renowned innovator from the Land of the Rising Sun. Founded in 1949, this Japanese trailblazer has unfurled an impressive tapestry of technological advancements in electron optics and analytical instruments. With its headquarters nestled in Tokyo, JEOL has been at the forefront of developing sophisticated tools such as scanning electron microscopes, nuclear magnetic resonance spectrometers, and mass spectrometers. These instruments have become indispensable for scientists and researchers across myriad fields, ranging from materials science to biotechnology. By focusing on high-quality precision and cutting-edge innovation, JEOL's products aid in unveiling the microscopic secrets of the world, empowering its users to explore realms of science once thought unreachable. What sets JEOL apart is its commitment not just to the science of today but to the possibilities of tomorrow. The company has consistently reinvested its profits into research and development, fostering a culture of perpetual innovation. By maintaining a comprehensive global sales and support network, JEOL ensures that its instruments are not only technologically advanced but also accessible to a worldwide clientele. This business model is reflective of their ability to generate revenue through both direct sales and ongoing service and support contracts, ensuring a steady revenue stream while bolstering relationships with research institutions, universities, and industries worldwide. Through this multifaceted approach, JEOL sustains its financial health, while solidifying its reputation as a catalyst for scientific discovery and technological progress.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on JEOL Ltd's most recent financial statements, the company has Net Margin of 15.5%.
You don't have any saved screeners yet